APOP stock holders are getting a 1:3 ratio of shares in the tie-up deal. The merger brings together Cellect's stem cell tech with Quoin's rare and orphan diseases focus. More
Combine Cannabis and Real Estate With Innovative Industrial Properties
IIPR stock isn't a direct play on the cannabis market, nor is it the cheapest stock. Yet, it's a worthy investment in a growing industry. More
Tesla’s China Problems Are Good News for NIO Stock
The fundamentals underlying NIO stock are strengthening significantly and rapidly, so buy shares on near-term weakness. More
ARVL Stock: 12 Things to Know As EV Play Arrival Starts Trading Today
ARVL stock is debuting on the Nasdaq today after shareholders gave the Arrival SPAC merger the green light. Here's what to know now. More
Amid Some Good News, The Outlook of Churchill Capital Corp IV Hasn’t Changed
Continuing to sport a huge valuation, CCIV stock still isn't worth buying after EV stocks lost momentum. More
BowX: Run, Don’t Walk, From the WeWork IPO
WeWork lost $3.2 billion last year and now calls itself a technology platform for creating flexible workspaces. More
Wait for Acasti Pharma Stock to Fall Further Before Buying
The future course of ACST stock depends largely on the company's lead drug candidate, CaPre. Any good news could send the shares higher. More
